News

As part of the agreement, the Juvenile Diabetes Research Foundation (JDRF) will provide $1 million in first-year funding to support preclinical safety and efficacy testing. The partnership is

Mylan believes that it is the first company to file a substantially complete abbreviated new drug application (ANDA) containing a paragraph IV certification for the product. The company

The data showed encouraging and durable anti-tumor activity in the three expanded dose groups tested thus far, as measured by prostate specific antigen (PSA) declines, radiographic findings, circulating

The license provides Enigma with access to claims of US patent that describe methods for monitoring nucleic acid amplification in real-time. This is the first such license Applied

Outpatient therapy with interleukin 21 (IL-21) and Nexavar as a second or third-line therapy for metastatic renal cell cancer was associated with anti-tumor activity, with manageable side effects.

The company has reported sales of $5.94 billion for the third quarter of 2008, a decrease of 2%, compared to $6.07 billion posted in the third quarter of

Lipsovir is a patented combination of hydrocortisone (an anti-inflammatory agent) and acyclovir (an antiviral agent) in a proprietary cream base developed by Medivir. The clinical Phase III program

In the study, which assessed the maximum tolerated dose, overall safety, pharmacokinetics and preliminary efficacy of BI 6727, a total of 50 patients were treated at doses of

The expanded and updated results continued to show that picoplatin can be safely administered with full-dose docetaxel and prednisone, the standard treatment for hormone-refractory prostate cancer (HRPC), with